GLS and neoplasm: The combined treatment with the glutaminase inhibitor CB-839 and the PI3K/aldolase inhibitor BKM120 consistently reduces cell growth of both A549 and HCT116 tumor xenografts, leading to a significant tumor reduction and prolonged survival without associated toxicity (Figs. 3 and S1).